MYX presentation at Jefferies Global Healthcare Conference
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA PRESENTATION AT THE 2024 JEFFERIES
GLOBAL HEALTHCARE CONFERENCE, NEW YORK CITY
06 June 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that
Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 2024 Jefferies
Global Healthcare Conference in New York City as follows:
Date:
Time:
Webcast:
Thursday, 6 June 2024
11:00am EDT (Friday, 7 June 2024 at 1.00am AEST)
Click Here
A copy of the presentation slides is attached.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne Pharma
also provides contract development and manufacturing services to clients worldwide. Mayne
Pharma has a 40 year track record of innovation and success in developing new oral drug delivery
systems. These technologies have been successfully commercialised in numerous products that
continue to be marketed around the world. To learn more about Mayne Pharma, please visit
maynepharma.com.
Mayne Pharma
Group Limited
MYX.ASX
Jefferies Global Healthcare
Conference
June 6, 2024
Shawn Patrick O’Brien
CEO and Managing Director
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited
Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or
implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major
customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● DORYX®, FABIOR®, KAPANOL®, LEXETTE®, RHOFADE® and SORILUX® are trademarks of Mayne Pharma. ANNOVERA®, BETADINE®, BIJUVA®, BRIMONIDINE®,
EPSOLAY®, FINACEA®, IMVEXXY®, KADIAN®, MIRVASO®, NEXTSTELLIS®, ORACEA®, SOOLANTRA®, VITAMEDMD®, WYNZORA® and ZILXI® are trademarks of
third parties.
2
Mayne Pharma: Improving patient access to life-enhancing medications
● Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing
branded pharmaceuticals.
Women’s Health
Dermatology
International
Reproductive Health
Proprietary Brands
• Flagship product NEXTSTELLIS®
• ANNOVERA® and vitaMedMD®
licensed in December 2022
• RHOFADE®, FABIOR®, SORILUX®,
DORYX®, LEXETTE®, WYNZORA®
CDMO
Specialty Partner Companies
Australian products
• Cosette, Upsher-Smith, Torrent,
GALDERMA, Sandoz, Encube
International products
Menopause Management
• BIJUVA® and IMVEXXY® licensed in
December 2022
20+ other dermatologics
3
Why Mayne Pharma?
Leading position in strong and growing Women’s Health market
4 novel products
One of the top 2 specialised women’s health companies in the US1
Building market leadership and scale in Dermatology
6 proprietary brands and 20+ AGs & generic dermatologics
Portfolio can fill 1 in 3 US Dermatology Retail Rx’s2
Capitalizing on unique patient Rx access platform
Platform spans the entire value chain, allowing Mayne Pharma to create a comprehensive, cost-effective experience
National rollout launched in January 2024; has demonstrated improved profitability per prescription
Growing revenue
1HFY24 revenue of A$187.9 million was up 43% from 2HFY23
Meaningful 2HFY23 to 1HFY24 growth in both Women’s Health (+45%) and Dermatology (+71%)
Returning to profitability
Achieved positive direct contribution3 in all three segments in 1HFY24
Total reported direct contribution of A$40.6 million in 1HFY24
1. Based on size of US Women’s Health Commercial Operations calling on OB/GYNs
2. IQVIA recent 12-month TRx totals by molecule, April 2024
3. Direct contribution calculated as gross margin less direct OPEX
4
FY2024 Goals
Deliver positive
direct contribution1
in all three
segments
● Achieved positive direct
contribution in all three
segments in 1HFY24
● On track for positive
direct contribution
margin in 2HFY24 and
full year
Return Company to
positive underlying
EBITDA in FY24
● Positive underlying
EBITDA of A$8.0m
achieved in 1HFY24
● On track for 2HFY24 and
full year
1. Direct contribution calculated as gross margin less direct OPEX
Optimize cost base
with OPEX and
other reductions of
>US$10m
● Reductions executed
1HFY24; OPEX added
with growth but at
lower rate
● Reductions of ~US$5m
achieved during 1HFY24
NEXTSTELLIS® run
rate breakeven
Return Company to
positive operating
cash generation in
FY24
● Achieved breakeven run
rate in December
● Majority of 1HFY24 cash
outflow related to
investing/financing; also
includes inventory build
for new product
launches
● Trade cycle growth, net
selling price (NSP)
improvements and
lower costs
● On track for positive
continuing operating
cash for 2HFY24 and the
full year
5
US Women’s Health
1HFY24 Performance
+45% revenue growth
● A leading position in strong and growing market
with four novel women’s healthcare products
● One of the top 2 specialized women’s health
companies in the US1
● Strong commercial infrastructure in place with sales
team of 94 able to reach target customers
● Three Orange Book NEXTSTELLIS® patents expiring
June 2036
REPRODUCTIVE
HEALTH
MENOPAUSE
MANAGEMENT
1.
2.
3.
Women's Health in USD'000
Total Revenue
Total Gross Profit
Total Gross Profit % of Revenue
Direct OPEX
2
Direct Contribution
Depreciation Add-Back
Earn-out liability
3
"Cash" Contribution
1HFY23
9,005
7,183
80%
(24,611)
(17,427)
347
(17,080)
2HFY23
32,667
29,096
89%
(30,310)
(1,215)
643
(1,877)
(2,449)
1HFY24
47,277
38,334
81%
(26,527)
11,807
579
(3,422)
8,964
→ NEXTSTELLIS® achieved breakeven run rate, trade cycle growth
+33% vs 2HFY23, NSP improvements, lower costs
→ Steady growth of ANNOVERA®, BIJUVA®, and IMVEXXY®
→ Cost initiatives executed in 2Q ~US$5m
→ Actively participating in getting US Affordable Care Act (ACA) as
an effective law for birth control
Based on size of US Women’s Health Commercial Operations calling on OB/GYNs.
Direct contribution calculated as gross margin less direct OPEX
Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability : portion of earnout liability related to revenues for the period
independent of timing / capitalised amount
6
Dermatology / Portfolio Products Division (PPD)
1HFY24 Performance
+71% revenue growth
● 6 proprietary brands and 20 generic dermatologics
● Portfolio can fill 1 in 3 US Dermatology Retail Rx’s1
● Building on market position with a profitable
pipeline of products to meet broader patient needs
● Differentiated channel strategy through specialty
pharmacy growth and online platforms like GoodRx
+20 generic
Dermatology
products
1.
2.
3.
4.
Derm in USD'000
Total Revenue
Total Gross Profit
Total Gross Profit % of Revenue
Direct OPEX
Direct Contribution 2
Depreciation Add-Back
Earn-out liability
3
"Cash" Contribution
1HFY23
7,495
(3,036)
-41%
(12,034)
(15,070)
1,861
(1,509)
(14,718)
2HFY23
30,878
10,226
33%
(9,269)
957
(998)
(41)
1HFY24
52,855
23,908
45%
(12,085)
11,823
581
(602)
11,802
→ Core portfolio performing well
→ New product launches driving growth - authorized generic
SOOLANTRA® and RHOFADE® (record market share achieved)4
→ Disintermediation (unique prescriber patient fulfilment model) pilot
project confirmed the value and need of the solution, positioning a
nationwide rollout in the US
IQVIA recent 12-month TRx totals by molecule, April 2024
Direct contribution calculated as gross margin less direct OPEX
Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability : portion of earnout liability related to revenues for the period independent of timing / capitalised amount
IQVIA March 2024, RHOFADE® market basket includes RHOFADE®, MIRVASO® and BRIMONIDINE® Gel and SOOLANTRA® market basket includes SOOLANTRA® (and generics), FINACEA®, FINACEA® Foam, EPSOLAY®, and ZILXI®.
7
Patient Ease of Access or Disintermediation Strategy
Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a
comprehensive, frictionless, transparent, and cost-effective experience
● Launched pilot program with GoodRx in 1HFY24 in Dermatology which further unlocked and confirms the value
of Adelaide Apothecary
● Physicians can now prescribe any Mayne Pharma product via GoodRx platform and patients will be triaged to a
partner pharmacy that delivers their product at the lowest out of pocket cost based on their insurance coverage
● If a Mayne Pharma product is not covered via insurance, patients are offered the option to utilise Adelaide
Apothecary to acquire our products directly for a cash price
● National rollout in January 2024, following positive feedback from the pilot program
● Use of this channel has yielded improvement in profitability per prescription while also offering enhanced
savings to patients
● Mayne Pharma continues to add new patients each week with many signing up for ongoing refills
8
International
1HFY24 Performance
● Improved financial profile
● 2-year agreement signed for the supply of
BETADINE®
● Expansion of KADIAN® /KAPANOL® into Canada,
Europe and Asia progressing
● 70% improvement in supply reliability in last 12
months
● Ongoing progress on significant capital and
system projects ($3.2m in 1HFY24)
1.
2.
International in AUD'000
Reported Revenue
Reported Gross Profit
Total Gross Profit % of Revenue
Direct OPEX
1
Direct Contribution
Depreciation Add-Back
Earn-out liability
2
"Cash" Contribution
1HFY23
27,626
8,876
32%
(6,052)
2,824
2,164
(808)
4,180
2HFY23
37,079
10,048
27%
(5,998)
4,050
1,983
6,033
Direct contribution calculated as gross margin less direct OPEX
Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability : portion of earnout liability related to revenues for the period
independent of timing / capitalised amount
1HFY24
34,608
10,480
30%
(6,057)
4,423
1,943
(82)
6,284
9
2HFY24 Outlook and Key Focus
Expected to grow both revenue and earnings 2H24 vs. 1H24
WOMEN’S HEALTH
• Continued growth across all Women’s
Health brands, continued operational
changes
• Ongoing evaluation of ROI on
marketing spend
• Continued growth driven primarily by:
DERMATOLOGY
• Maintenance of margin profile via more
volumes from branded products,
continuous pricing management
• Additional new product launches to further
build out portfolio and grow revenues
• Unique prescriber patient fulfilment
process transition from pilot to fully scaled
operation
• Record market shares of:
Authorized Generic
Continued revenue
growth with improving
cost leverage and
discipline
Return company to
positive cash flow
generation (Continuing
operations)
SOOLANTRA®
10
Fireside Chat
Q&A
Shawn Patrick O’Brien CEO
Mayne Pharma
Group Limited
ASX:MYX
You deserve tomorrow.
11
Share your feedback
Discover